Veeva Systems

KYCO: Know Your Company

Reveal Profile

14 November 2025

1) Overview of the Company

Veeva Systems Inc. is a leading global provider of industry-specific, cloud-based software solutions for the life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner and Matt Wallach, the company pioneered the “Industry Cloud” category by developing specialized applications exclusively for pharmaceutical, biotechnology, and medical device companies. As of fiscal year 2025, Veeva serves over 1,500 customers ranging from the world’s largest pharmaceutical companies to emerging biotechs, achieving total revenues of $2.747 billion, representing a 16% increase year-over-year.

The company operates through two primary business segments: Veeva Commercial Solutions, which generated $305.4 million in subscription services revenue in Q1 2026, and Veeva R&D Solutions, which produced $329.4 million in subscription services revenue during the same period. Veeva’s comprehensive product portfolio includes over 50 applications spanning clinical trial management, regulatory submissions, quality management, customer relationship management, and data analytics solutions. The company’s flagship offerings include Veeva CRM for pharmaceutical sales forces, Veeva Vault Platform for content and data management, and specialized applications for clinical operations, regulatory affairs, and quality assurance.

Veeva maintains a global presence with employees across North America, Europe, Asia-Pacific, and Latin America, serving customers in 27 languages across multiple regulatory jurisdictions. The company trades on the New York Stock Exchange under the ticker symbol “VEEV” and achieved a market capitalization of approximately $48.33 billion as of November 2025. In 2021, Veeva became the first publicly traded company to convert to a Public Benefit Corporation, demonstrating its commitment to balancing stakeholder interests including customers, employees, shareholders, and the industries it serves.

The company’s financial strength is evidenced by its debt-free balance sheet, holding over $6 billion in cash and short-term investments as of Q1 2026, and generating operating cash flow of $877 million in the first quarter alone. Veeva achieved its previously announced 2025 revenue run rate goal of $3 billion during Q1 2026 and has established a new target of $6 billion in revenue by 2030. The subscription-based business model generates approximately 84% of total revenue, with professional services comprising the remainder, reflecting strong recurring revenue characteristics.

2) History

Veeva Systems Inc. was founded in January 2007 by Peter Gassner and Matt Wallach in Pleasanton, California, emerging from a shared vision that cloud computing would follow the same evolution pattern as previous technology waves, becoming increasingly specialized for specific industries. Initially operating under the name Verticals onDemand, Inc., the company rebranded to Veeva Systems Inc. in April 2009, reflecting its focus on building the first cloud-based software solutions specifically designed for the life sciences industry.

Peter Gassner brought extensive enterprise software experience from his previous roles at IBM Silicon Valley Lab, PeopleSoft, and Salesforce, where he served as Senior Vice President of Technology and helped develop core platform capabilities. His co-founder Matt Wallach contributed deep pharmaceutical industry expertise and customer relationships, creating the unique combination of Silicon Valley technology leadership and life sciences domain knowledge that would define Veeva’s approach.

The company achieved rapid early milestones with the launch of Veeva CRM in 2008, securing a $4 million Series A funding round led by Emergence Capital Partners in June 2008. Built on the Salesforce platform, Veeva CRM gained remarkable market penetration, capturing over 80% of the pharmaceutical CRM market by 2012 and establishing relationships with major industry players including Johnson & Johnson, Pfizer, Novartis, and Amgen. This early success demonstrated the validity of Veeva’s vertical cloud strategy and positioned the company for broader expansion.

A transformational moment came in February 2011 with the introduction of Veeva Vault, a regulated content management platform that expanded the company’s offerings beyond CRM into document and data management for clinical trials, regulatory submissions, and quality processes. This marked Veeva’s evolution from a single-product CRM company to a comprehensive cloud platform provider, significantly expanding its total addressable market within life sciences.

Veeva’s successful initial public offering occurred on October 16, 2013, when the company listed on the New York Stock Exchange under the ticker symbol “VEEV” at $20 per share, raising over $217 million with shares closing at $37.16 on the first day of trading. At the time of the IPO, Veeva had grown to over 650 employees and achieved $129.5 million in annual revenue with three consecutive years of profitability, validating the sustainability of its business model.

The company continued strategic expansion through both organic development and targeted acquisitions. In October 2015, Veeva acquired Zinc Ahead for $130 million to enhance its content management capabilities, followed by additional acquisitions including Crossix in 2019 for $430 million, adding patient data analytics to its portfolio. These acquisitions strengthened Veeva’s position across the pharmaceutical value chain from research and development through commercialization.

A significant corporate governance milestone occurred in February 2021 when Veeva became the first publicly traded company to convert to a Public Benefit Corporation, legally committing to balance the interests of customers, employees, society, and shareholders. This conversion, approved by over 99% of shareholders, reinforced Veeva’s long-term commitment to serving the life sciences industry’s mission of improving patient outcomes.

The company has consistently demonstrated strong financial performance, reaching $1 billion in annual revenue by 2018 and achieving $2.747 billion in total revenues for fiscal year 2025, representing sustained double-digit growth rates throughout its public company history. By 2025, Veeva served over 1,500 customers ranging from emerging biotechs to the world’s largest pharmaceutical companies, establishing itself as the dominant cloud software provider for the life sciences industry with operations spanning North America, Europe, Asia-Pacific, and Latin America.

3) Key Executives

Peter Gassner serves as Founder and Chief Executive Officer of Veeva Systems Inc., a position he has held since January 2007. With over 30 years of enterprise software experience, Gassner has been at the forefront of major technology transitions from mainframe computing at IBM Silicon Valley Lab to client-server architecture at PeopleSoft, cloud computing at Salesforce, and industry cloud software at Veeva. He holds a bachelor of science degree in computer science from Oregon State University and currently serves on the boards of directors of both Veeva and Zoom Video Communications. Gassner led Veeva’s conversion to a Public Benefit Corporation in 2021, making it the first publicly traded company to achieve this designation.

Tom Schwenger serves as President and Chief Customer Officer, responsible for field functions including sales and services. Appointed to this role in September 2019, Schwenger brings over 30 years of life sciences industry expertise, having built high-performing teams driving strategy and technology transformations for major pharmaceutical, biotech, and medical device companies. Prior to joining Veeva, he was responsible for Accenture’s Northeast Products Industries Practice and led the growth of Accenture’s North American Life Sciences Practice. He holds a bachelor of science degree in business and statistics from Penn State University.

Brian Van Wagener was appointed Chief Financial Officer in September 2024, responsible for finance, accounting, legal, investor relations, and treasury functions. Van Wagener previously worked in various Veeva roles for over five years, including chief of staff to the CEO and vice president of global sales operations. Prior to his current role, he served as senior vice president of go-to-market strategy and operations at BetterUp and held executive leadership positions at Frontier Communications. He graduated with a bachelor of arts degree from Dartmouth College and earned a master of business administration from Northwestern University School of Management.

Nitsa Zuppas serves as President and Chief of Staff, helping set, communicate, and execute company direction. She previously served as Veeva’s chief marketing officer from 2013 to 2024, guiding the company through its IPO and growth to become the industry cloud leader. Zuppas has over 30 years of marketing and technology experience with particular expertise in enterprise software and establishing category leadership. Before joining Veeva, she was a senior executive at First Virtual Group and managed the Siebel Foundation, where her leadership resulted in recognition as the third most effective philanthropy globally by Barron’s magazine.

Howie Hsueh serves as Senior Vice President of Global Services, responsible for ensuring customer success globally and leading Veeva’s professional services, customer success, and product support teams. He joined Veeva in 2012 to lead some of the first Vault implementations before building the professional services organization for Veeva’s Development Cloud. Prior to Veeva, Hsueh spent eight years in various leadership roles providing regulatory consulting and software services to help companies transform their electronic submissions processes. He holds a bachelor’s degree in journalism from Rutgers University and chairs the Veeva Asian Community.

Vivian Welsh serves as Chief People Officer, responsible for global employee success programs and teams, ensuring that people processes and culture scale effectively as the company continues to grow. Welsh has been in the software industry for nearly 20 years since starting her career at PeopleSoft, bringing software implementation and project management experience with strong functional and technical product expertise. She pioneered Veeva’s university graduate development programs spanning engineering, services, and sales functions, and re-invented the company’s talent attraction model for experienced hires. Welsh holds a bachelor of business administration degree in management information systems from Florida International University.

Catherine Allshouse serves as Executive Vice President of Internal Operations, leading Veeva’s CIO, CISO, Quality & Compliance, Technical Operations, and Facilities & Workplace teams while coordinating across Finance, Legal, and Employee Success functions. She has extensive experience spanning commercial and industrial software business from strategy through delivery. Previously, Allshouse served as COO, CIO, and Secretary at the KnowledgeWorks Foundation and was responsible for the software engineering division at the Kroger Company. She spent 12 years at PeopleSoft in various executive roles and currently serves on the board of directors of Boulder, Colorado software company Stateless.

Josh Faddis serves as Senior Vice President and General Counsel, managing all aspects of the legal function including commercial contracting, IP management, litigation management, governance and compliance, and corporate citizenship. He has over 20 years of experience managing legal needs for cloud software companies from early growth stages to maturity as multi-billion dollar public companies. Prior to joining Veeva, Faddis was senior vice president and general counsel at Taleo, overseeing the legal function as the company grew from $12 million to $325 million in annual revenues and its eventual sale for $2.1 billion. He received his J.D. from Georgetown University Law Center and his bachelor of arts degree from Texas A&M University.

Laura Moran serves as President of Global Commercial, overseeing commercial sales teams and solution consultants excluding Asia. She brings nearly 30 years of global work experience across multiple industries, including over 20 years in life sciences. Prior to joining Veeva, Moran was a partner in McKinsey & Company’s pharmaceutical and medical products practice, holding global and US leadership roles across various service lines. She also worked at leading professional services organizations including Bain & Company and PricewaterhouseCoopers, with experience living and working in Europe, the US, and Asia. Moran earned her master of business administration from the Wharton School of Business at the University of Pennsylvania.

Erik Smith serves as Senior Vice President of Global R&D and Quality, responsible for global R&D and Quality sales and customer success. He joined Veeva over ten years ago to build the R&D and Quality sales program, working with both emerging and large enterprise biopharmaceutical companies. Prior to Veeva, Smith served in sales leadership roles at NextDocs Corporation and US Data Management, beginning his career at Abbott Diagnostics where he accumulated over 20 years of sales executive experience in life sciences. He earned his bachelor of science degree from Arizona State University, where he played baseball.

4) Ownership

Veeva Systems Inc. operates as a publicly traded company on the New York Stock Exchange under the ticker symbol “VEEV” with a market capitalization of approximately $48.33 billion as of November 2025. The company maintains a dual-class common stock structure consisting solely of Class A common stock with one vote per share, after the Class B common stock was converted to Class A common stock on October 15, 2023. As of the most recent reporting period, Veeva has 163.91 million shares outstanding with a free float of approximately 147.46 million shares, representing 90.83% of total shares available for public trading.

Institutional investors dominate Veeva’s ownership structure, holding approximately 88.20% of outstanding shares, reflecting strong institutional confidence in the company’s business model and growth prospects. The Vanguard Group, Inc. serves as the largest institutional shareholder with 15.43 million shares representing 9.41% of the company, valued at approximately $4.6 billion as of September 30, 2025. BlackRock, Inc. maintains the second-largest institutional position with 10.88 million shares representing 6.64% ownership, followed by FMR LLC with 5.71 million shares representing 3.48% of the company.

Peter Gassner, the company’s founder and CEO, represents the largest individual shareholder with 12.27 million shares constituting 7.49% ownership, valued at approximately $3.3 billion. This significant founder ownership aligns management interests with shareholder value creation and demonstrates long-term commitment to the company’s strategic direction. Other notable insider holdings include Matthew J. Wallach, co-founder and current board member, who owns approximately 356,000 shares. Total insider ownership across executives and directors represents approximately 8.55% of outstanding shares, providing meaningful alignment between management and shareholder interests.

The company’s ownership structure has evolved significantly since its 2013 initial public offering, with institutional ownership increasing substantially as Veeva achieved S&P 500 inclusion and demonstrated consistent financial performance. Recent institutional trading activity shows net inflows of $9.50 billion over the past 12 months from 779 institutional buyers, compared to $3.49 billion in outflows from 532 institutional sellers, indicating overall institutional confidence. Principal institutional holders include T. Rowe Price Investment Management with 2.70% ownership, Principal Financial Group with 2.35%, and State Street Corporation with 2.09% of outstanding shares.

Veeva’s capital structure reflects a debt-free balance sheet with total stockholders’ equity of $5.83 billion as of January 31, 2025, representing a 25.6% increase from the prior year. The company’s financial strength is further evidenced by its cash and short-term investments totaling over $5.1 billion, providing substantial financial flexibility for strategic initiatives, acquisitions, or shareholder returns. In early 2024, Veeva initiated its first-ever share repurchase program authorizing up to $500 million in stock buybacks, demonstrating management’s confidence in the company’s intrinsic value and commitment to returning capital to shareholders.

The ownership distribution reflects a mature public company profile with strong institutional backing, meaningful founder involvement, and broad public participation through mutual funds and ETFs. Major mutual fund holders include Vanguard Total Stock Market Index Fund with 2.87% ownership and Vanguard Mid-Cap Index Fund with 1.97% ownership, providing stable, long-term oriented capital. This ownership structure supports Veeva’s strategic positioning as a leading provider of cloud-based software solutions for the life sciences industry while maintaining the governance benefits associated with its 2021 conversion to a Public Benefit Corporation structure.

5) Financial Position

Veeva Systems Inc. trades on the New York Stock Exchange under the ticker symbol “VEEV” with a market capitalization of approximately $48.33 billion as of November 2025. The company’s stock has demonstrated strong performance over the past year, gaining 25.47% and delivering a 41.59% year-to-date return, significantly outperforming broader market indices. Veeva’s shares have traded within a 52-week range of $201.54 to $310.50, reflecting both the volatility in technology stocks and the company’s strong fundamental performance throughout fiscal year 2025.

The company’s financial performance over the past five years demonstrates consistent growth and profitability metrics that distinguish it among enterprise software providers. Total revenues have grown from $1.465 billion in fiscal year 2021 to $2.747 billion in fiscal year 2025, representing a compound annual growth rate of approximately 17% over this period. Subscription services revenues, which comprise approximately 83% of total revenue, increased 20% year-over-year to $2.285 billion in fiscal year 2025, demonstrating the strength of Veeva’s recurring revenue model. The company achieved its previously announced 2025 revenue run rate goal of $3 billion during Q1 2026 and has established a new target of $6 billion in revenue by 2030.

Veeva’s profitability metrics reflect exceptional operational efficiency for a software business. Operating income increased 61% year-over-year to $691.4 million in fiscal year 2025, yielding an operating margin of 25.2% compared to 18.2% in the prior year. Net income reached $714.1 million in fiscal year 2025, representing a 36% increase from the previous year and generating a net profit margin of 26.0%. On a non-GAAP basis, which excludes stock-based compensation and other items, the company achieved an operating margin of approximately 42%, highlighting the underlying profitability of its subscription-based business model.

The company’s balance sheet reflects exceptional financial strength with total assets of $7.34 billion and total stockholders’ equity of $5.83 billion as of January 31, 2025. Veeva maintains a debt-free capital structure, holding over $6.4 billion in cash and short-term investments as of Q2 2026, providing substantial financial flexibility for strategic initiatives, acquisitions, or shareholder returns. Current assets of $6.99 billion compared to current liabilities of $1.26 billion yield a current ratio of 5.57, indicating strong liquidity and the ability to meet short-term obligations. The company’s debt-to-equity ratio is effectively zero, demonstrating conservative financial management and minimal financial risk.

Cash flow generation remains robust with operating cash flow of $1.115 billion in the first six months of fiscal year 2026, compared to $856 million in the same period of the prior year. Free cash flow reached $1.328 billion on a trailing twelve-month basis, representing a free cash flow margin of approximately 45% and demonstrating the company’s ability to convert earnings into cash. This strong cash generation has enabled Veeva to return capital to shareholders through its first-ever share repurchase program, authorizing up to $500 million in stock buybacks initiated in early 2024.

Valuation metrics reflect investor confidence in Veeva’s growth prospects, though the stock trades at premium multiples compared to broader software industry averages. The company trades at a forward price-to-earnings ratio of approximately 37x based on fiscal year 2026 estimates and a price-to-sales ratio of 16.2x on a trailing twelve-month basis. These valuations, while elevated, are supported by the company’s industry-leading margins, predictable subscription revenue model, and dominant market position in life sciences cloud software. Return on equity of 13.7% and return on assets of 11.3% demonstrate efficient capital allocation and strong profitability relative to invested capital.

Industry-specific risks include potential reductions in pharmaceutical and biotechnology R&D spending, which could impact demand for Veeva’s solutions, and increasing competition from larger enterprise software providers attempting to penetrate the life sciences market. The company faces foreign exchange exposure given its international operations, though this represents a relatively small portion of total revenue. Additionally, Veeva’s concentration in the life sciences industry, while providing deep domain expertise, creates dependency on the continued growth and technology adoption within this sector. The company has begun diversifying into adjacent regulated industries including consumer products, food and beverage, and specialty chemicals, though these represent a small percentage of current revenue.

6) Market Position

Veeva Systems Inc. holds a commanding position in the global life sciences cloud software market, maintaining an estimated 80% market share in pharmaceutical customer relationship management systems and serving over 1,500 customers ranging from the world’s largest pharmaceutical companies to emerging biotechnology firms. The company has achieved remarkable market penetration, with 19 of the top 20 life sciences companies and over 80% of approximately 500,000 global pharmaceutical sales representatives utilizing Veeva CRM solutions. This dominant position reflects Veeva’s strategic focus on industry-specific solutions rather than attempting to compete in broader enterprise software markets against horizontal providers like Salesforce or Oracle.

The company’s market leadership extends across multiple product categories within its comprehensive platform strategy. Veeva’s Development Cloud solutions serve over 1,078 customers, while Commercial Cloud applications serve 693 customers, with significant overlap as many organizations deploy multiple Veeva products across different business functions. In the clinical trial management space, more than 500 companies utilize at least one Veeva Vault Clinical solution, with over 85 customers deploying both clinical operations and clinical data management products from Veeva. This cross-selling success demonstrates the effectiveness of Veeva’s integrated platform approach and contributes to its strong customer retention rates exceeding 95% annually.

Veeva’s competitive positioning is strengthened by substantial intellectual property assets, including over 88 active patents globally covering core technologies across customer relationship management, content management, data visualization, and electronic communications systems. The company’s proprietary technology foundation includes innovations in privacy-preserving data mining, controlled content repositories, and multi-tenant cloud architectures that provide technical barriers to entry for potential competitors. Notable patents include foundational work on double-blinded privacy-safe distributed data mining protocols and systems for controlling electronic communications in regulated environments.

The competitive landscape features several categories of rivals, each with distinct positioning relative to Veeva’s specialized approach. Direct competitors include IQVIA’s Orchestrated Customer Engagement platform, which leverages IQVIA’s extensive healthcare data assets to provide analytics-driven CRM capabilities, and Medidata Solutions (acquired by Dassault Systèmes), which focuses primarily on clinical trial management and data capture. Broader enterprise software providers such as Oracle, SAP, and Salesforce offer life sciences-specific modules within their general-purpose platforms, but these typically require significant customization to match Veeva’s industry-specific functionality. Emerging competitors include specialized point solutions and AI-driven platforms attempting to address specific segments of Veeva’s market.

Veeva’s strategic differentiation is anchored in its industry cloud approach, combining deep life sciences domain expertise with comprehensive platform capabilities spanning the entire product lifecycle from research through commercialization. The company’s conversion to a Public Benefit Corporation in 2021 further distinguishes it from competitors by legally codifying its commitment to balancing stakeholder interests including customers, employees, and the industries it serves. This positioning resonates strongly with life sciences customers who value long-term partnerships and alignment with their mission to improve patient outcomes.

Customer relationships represent a core competitive advantage, with Veeva maintaining direct engagement with senior executives at major pharmaceutical companies through dedicated account teams and strategic consulting services. The company’s customer success organization provides 24/7 global support across all time zones, ensuring continuous availability for mission-critical operations. Veeva’s customer conferences and user communities, including events like the annual R&D and Quality Summit and Commercial Summit, facilitate knowledge sharing and strengthen relationships within the life sciences ecosystem.

Recent strategic partnerships have expanded Veeva’s market position and capabilities. The August 2025 resolution of disputes with IQVIA resulted in comprehensive commercial and clinical partnerships, enabling mutual third-party access agreements that allow IQVIA data to be used within Veeva applications and vice versa. This collaboration removes previous competitive barriers and enhances Veeva’s value proposition by providing customers access to best-in-class data and analytics from both companies. Similarly, the October 2025 partnership with OpenEvidence to develop Open Vista represents Veeva’s expansion into AI-powered clinical decision support and patient engagement.

Veeva’s market position is reinforced by consistent industry recognition and awards. For three consecutive years (2022-2024), Veeva MedTech has been named “Best Overall MedTech Software” by the MedTech Breakthrough Awards program, highlighting its leadership in medical device and diagnostics software. The company has also received multiple recognitions from Fortune magazine, including inclusion in the Fortune Future 50 and Fortune’s Fastest-Growing Companies list for five consecutive years, demonstrating sustained excellence in growth and market performance.

The company’s distribution strategy leverages a robust partner ecosystem comprising over 1,000 certified partners, including premier services partners such as Accenture, Cognizant, and HCLTech who provide implementation and managed services capabilities. This partner network extends Veeva’s reach and implementation capacity while ensuring quality delivery through rigorous certification programs and ongoing training requirements. Veeva maintains different partnership tiers (Premier, Gold, Silver, Base) based on customer engagement, collaboration experience, and certifications, ensuring customers have access to appropriately skilled implementation partners.

Regulatory positioning provides Veeva with significant competitive advantages, as its solutions are designed from the ground up to meet complex compliance requirements including FDA 21 CFR Part 11 for electronic records, Good Clinical Practice guidelines, and various international regulatory frameworks. This built-in compliance capability reduces implementation risk and time-to-value for customers compared to generic software platforms that require extensive customization to achieve regulatory compliance. Veeva’s regulatory expertise is demonstrated through its ability to adapt quickly to evolving requirements, such as supporting the European Medicines Agency’s new IDMP (Identification of Medicinal Products) standards and eCTD 4.0 implementation requirements.

Looking forward, Veeva’s market position appears well-positioned for continued expansion through several growth vectors. The company has established a long-term revenue target of $6 billion by 2030, representing more than double its current scale and implying continued market share gains and expansion into adjacent opportunities. Key growth drivers include the ongoing transition of existing Veeva CRM customers to the new Vault CRM platform, expansion of clinical and quality solutions into mid-market segments through products like Veeva Basics, and the introduction of AI-powered capabilities across all product lines through the Veeva AI initiative launching in December 2025.

7) Legal Claims and Actions

Veeva Systems Inc. has been involved in several significant legal matters over the past decade, with the most prominent being its complex eight-year litigation dispute with IQVIA Inc. that concluded in August 2025. The IQVIA litigation originated on January 10, 2017, when IQVIA filed a complaint in the U.S. District Court for the District of New Jersey alleging that Veeva used unauthorized access to proprietary IQVIA data to improve its software and data products and that Veeva’s software was designed to steal IQVIA trade secrets. IQVIA further alleged that Veeva intentionally gained unauthorized access to IQVIA proprietary information to gain an unfair advantage in marketing its products and made false statements concerning IQVIA’s conduct and data security capabilities.

Veeva responded with substantial counterclaims filed on March 13, 2017, alleging that IQVIA, as the dominant provider of data for life sciences companies, abused monopoly power to exclude Veeva OpenData and Veeva Network from their respective markets. The counterclaims alleged that IQVIA engaged in various tactics to prevent customers from using Veeva’s applications and deliberately raised costs and increased difficulty for customers attempting to switch from IQVIA data to Veeva’s data products. Veeva’s counterclaims sought injunctive relief, monetary damages exceeding $200 million, and attorneys’ fees under federal and state antitrust laws, California’s Unfair Practices Act, and common law claims for intentional interference with contractual relations and prospective economic advantage.

The IQVIA litigation expanded with additional actions, including the Veeva Nitro Action filed on July 18, 2019, in which Veeva alleged that IQVIA engaged in anticompetitive conduct regarding Veeva Nitro and other software applications including Veeva Andi, Veeva Align, and Veeva Vault MedComms. A significant development occurred on May 7, 2021, when the U.S. District Court issued sanctions against Veeva on multiple occasions for discovery violations, including findings that Veeva engaged in massive destruction of evidence, engaged in a cover-up of wrongdoing, and repeatedly made false statements about its actions. The court imposed multiple adverse jury instructions, limitations on the use of evidence at trial, and awarded legal fees and costs to IQVIA as sanctions.

The IQVIA litigation was ultimately resolved through a comprehensive settlement agreement entered into on August 13, 2025, under which neither party paid damages to the other and both parties agreed to dismiss with prejudice all claims and counterclaims currently pending. As part of the resolution, Veeva made a one-time payment of approximately $31 million to law firms that represented the company under previously disclosed outcome-based fee arrangements. The settlement also established commercial and clinical partnerships between the companies, allowing mutual third-party access to data and software for customer implementations.

A separate major litigation matter involved Medidata Solutions, Inc., which filed a complaint on January 26, 2017, in the U.S. District Court for the Southern District of New York against Veeva and five individual Veeva employees who previously worked for Medidata. The complaint alleged that Veeva induced and conspired with the individual employees to breach their employment agreements, including non-compete and confidentiality provisions, and to misappropriate Medidata’s confidential and trade secret information. After four days of jury trial, the court granted Veeva’s motion for judgment as a matter of law on July 15, 2022, thereby resolving the case in favor of Veeva. Medidata filed an appeal in the Second Circuit Court of Appeals on January 3, 2023, but on January 10, 2024, Veeva and Medidata filed a joint stipulation to dismiss Medidata’s appeal, which was granted by the court on January 18, 2024.

Veeva also faces ongoing litigation with Mednet Solutions, Inc., which filed a complaint on July 14, 2020, in Minnesota state court against Veeva and a former Mednet employee who joined Veeva. The complaint alleged that the employee improperly accessed Mednet’s computer systems after joining Veeva in violation of his employment agreement to misappropriate Mednet’s confidential and trade secret information for Veeva’s benefit. The case was removed to the U.S. District Court for the District of Minnesota on December 9, 2020, and has been amended twice to include additional factual allegations and direct claims against Veeva for misappropriation. The matter remains in the discovery phase of litigation with no trial date set.

In addition to defensive litigation, Veeva has proactively filed lawsuits to protect employee rights and combat what it views as unfair business practices. On July 18, 2017, Veeva filed a lawsuit in the Superior Court of California against three companies – Medidata, QuintilesIMS, and Sparta – for using illegal provisions in their employment agreements, including post-termination non-competes and overly broad confidentiality and non-disparagement clauses that restrict employees’ ability to change jobs. This litigation was part of Veeva’s broader advocacy against non-compete agreements and support for employee mobility rights.

Recent patent litigation includes Veeva Systems Inc. v. Tact.ai Technologies, Inc. and Aktana, Inc., filed in the U.S. District Court for the District of Delaware in 2023. The case involves three Veeva patents related to computer software for storing, displaying, and transmitting business information, with Veeva alleging infringement by the defendants’ software products designed for the life sciences industry. On June 5, 2024, the court denied Aktana’s motion to dismiss under the Alice Corp. patent eligibility standard, finding that Aktana failed to demonstrate that Veeva’s patents claim ineligible subject matter. The court also denied Aktana’s motion to dismiss for failure to adequately allege infringement, allowing the case to proceed to discovery.

Most recently, Veeva filed a trademark infringement lawsuit against Microsoft in February 2025, alleging that Microsoft’s “Viva” software suite creates brand confusion with Veeva’s trademark. The suit seeks to block Microsoft’s use of the name and requests unspecified damages. Additional ongoing matters include Veeva Systems Inc. v. H1 Insights Inc., filed on September 16, 2025, in California Superior Court, Alameda County, involving claims for declaratory judgment and unfair competition.

The company’s legal expenses related to the IQVIA litigation matters included partial contingency fee arrangements with certain law firms, pursuant to which the firms were entitled to an agreed portion of any damages recovered from IQVIA or payment of success fees based on achievement of certain outcomes. While Veeva was unable to estimate the liability related to these success fees prior to settlement, the ultimate $31 million payment to law firms in connection with the IQVIA settlement resolution represented the materialization of these contingent obligations.

8) Recent Media

In February 2025, Veeva Systems Inc. filed a trademark infringement lawsuit against Microsoft, alleging that Microsoft’s “Viva” software suite creates brand confusion with Veeva’s trademark. The lawsuit, filed in federal court, seeks to block Microsoft’s use of the “Viva” name and requests unspecified damages, arguing that the similarity between “Viva” and “Veeva” could confuse customers and dilute Veeva’s brand recognition in the market.

In August 2025, Veeva announced the resolution of its eight-year legal dispute with data firm IQVIA, which included the dismissal of all pending claims without any damages paid by either party. The agreement established long-term commercial and clinical partnerships, enabling customers to use IQVIA’s data within Veeva’s platforms and vice-versa. As part of the settlement, Veeva disclosed a one-time payment of approximately $31 million to its law firms to cover litigation fees under previously disclosed outcome-based fee arrangements.

The company reported strong financial performance through fiscal year 2025, which ended January 31, 2025. Total revenues increased 16% year-over-year to $2.747 billion, while subscription services revenue grew 20% to $2.285 billion, demonstrating the strength of Veeva’s recurring revenue model. For the first quarter of fiscal 2026, ending April 30, 2025, total revenues reached $676.2 million, representing a 17% increase from the same quarter in the prior year.

In September 2024, Veeva announced the appointment of Brian Van Wagener as its new Chief Financial Officer, effective immediately. Van Wagener, a returning company executive who previously worked in various Veeva roles for over five years, replaced interim CFO Tim Cabral, who remained on the company’s Board of Directors. Van Wagener brings extensive experience from his previous roles including chief of staff to the CEO and vice president of global sales operations at Veeva.

Throughout 2024, Veeva advanced its strategic focus on artificial intelligence and platform expansion. In April 2024, the company launched the Veeva AI Partner Program to facilitate the development of generative AI solutions integrated with Veeva Vault applications, providing a high-speed “Direct Data API” and sandbox environments for partner development. In September 2024, Veeva expanded its Vault CRM Suite in the Asia-Pacific region with the introduction of Vault CRM Service Center, designed for inside-sales and contact-center teams.

9) Strengths

Veeva Systems Inc. maintains an extraordinary market position within the life sciences industry, capturing over 80% market share in pharmaceutical customer relationship management systems and serving over 1,500 customers globally, including 19 of the top 20 life sciences companies. The company’s dominance is reflected in its exceptional customer retention metrics, with over 95% annual retention rates and net dollar retention consistently exceeding 120%. This market leadership translates into predictable revenue growth, as evidenced by over 85% of new sales coming from existing customers through successful land-and-expand strategies. The company’s average customer relationship spans multiple decades, with enterprise clients paying over $1 million annually and many exceeding $20 million in annual spending.

Veeva’s strategic focus exclusively on the life sciences industry has created unparalleled domain expertise that competitors struggle to match. The company’s solutions incorporate industry-specific workflows, regulatory requirements, and compliance frameworks that are built into the platform rather than retrofitted. This specialization is evidenced by the company’s ability to support complex regulatory environments including FDA 21 CFR Part 11, EU GMP Annex 11, and emerging standards like ISO IDMP. Veeva’s deep industry knowledge is reflected in its product development, with over 50 applications spanning clinical trial management, regulatory submissions, quality management, and commercial operations, all designed specifically for life sciences workflows.

The Veeva Vault Platform provides a unified foundation that manages data, content, and workflows together in a single system, eliminating the data silos that plague many life sciences organizations. This integration enables seamless collaboration across clinical, regulatory, quality, and commercial functions, with real-time data flow between applications. The platform’s architecture supports end-to-end business processes, from drug discovery through commercialization, providing customers with a single source of truth for all regulated content and data. The unified platform approach reduces integration complexity and total cost of ownership while improving data integrity and compliance across the enterprise.

Veeva demonstrates exceptional financial performance with industry-leading profitability metrics, including operating margins of 25.2% in fiscal year 2025 and net profit margins of approximately 26%. The company maintains a debt-free balance sheet with over $6 billion in cash and short-term investments, providing substantial financial flexibility for strategic initiatives and acquisitions. Veeva’s subscription-based business model generates approximately 84% of total revenue from recurring sources, ensuring predictable cash flow and high-quality earnings. The company’s capital efficiency is evidenced by its ability to achieve $2.747 billion in annual revenue while raising only $7 million in total venture funding before its IPO.

Veeva invests approximately 25% of revenue in research and development, totaling $693 million in fiscal year 2025, enabling continuous platform innovation and new product development. The company delivers three major product releases annually, ensuring customers always have access to the latest features and regulatory updates without disruptive upgrade cycles. Recent innovations include the introduction of Veeva AI agents built into the Vault Platform, providing industry-specific artificial intelligence capabilities that enhance productivity and decision-making. Veeva’s innovation pipeline includes advanced analytics, AI-powered insights, and next-generation clinical trial technologies that position the company at the forefront of life sciences digital transformation.

Veeva operates globally with deep understanding of local regulatory requirements across multiple jurisdictions, supporting customers in 27 languages and maintaining compliance with diverse international standards. The company’s global infrastructure includes dedicated regional teams and data centers that ensure optimal performance and regulatory compliance across North America, Europe, Asia-Pacific, and Latin America. This global reach is complemented by local expertise in market-specific requirements, from Japanese pharmaceutical regulations to European GDPR compliance, enabling seamless international expansion for life sciences customers.

Veeva has cultivated a comprehensive partner ecosystem comprising over 1,000 certified partners, including premier systems integrators such as Accenture, Cognizant, and HCLTech that extend implementation capacity and ensure quality delivery. The company maintains strategic relationships with industry leaders and has recently established partnerships with organizations like IQVIA, enabling mutual data access and enhanced customer value propositions. Veeva’s partner certification programs ensure high-quality implementations and ongoing support, while its extensive network of content partners, AI partners, and technology integrators provides customers with comprehensive solution coverage.

Veeva’s conversion to a Public Benefit Corporation in 2021 demonstrates its commitment to balancing stakeholder interests and long-term value creation beyond shareholder returns. This governance structure legally codifies the company’s commitment to customers, employees, and the industries it serves, providing stability and alignment in strategic decision-making. The company’s founder-led culture, with CEO Peter Gassner maintaining significant equity ownership, ensures long-term strategic consistency and alignment with shareholder interests. Veeva’s corporate citizenship initiatives and commitment to advancing the life sciences industry’s mission to improve patient outcomes further strengthen its reputation and customer relationships.

10) Potential Risk Areas for Further Diligence

Veeva Systems Inc. faces substantial execution risk through 2030 as it migrates its flagship CRM product from the Salesforce platform to its proprietary Vault platform, affecting thousands of users across hundreds of enterprise customers. This multi-year migration presents significant operational challenges including potential data loss during migration, extensive retraining requirements, and the complexity of transferring customer configurations while maintaining regulatory compliance and avoiding business disruption. The company has acknowledged that over 300 customers are currently in the migration pipeline, with expectations that two-thirds of migrations will occur during 2026-2027. Any technical issues, delays in Vault CRM platform development, or customer resistance to change could impact customer satisfaction and retention during this critical transition period.

Veeva Systems Inc. experienced significant operational disruptions in April 2024 when its centralized Vault authentication cluster became overloaded, resulting in outages on April 22, 23, and 24 that affected all global Vault deployments. The authentication cluster serves as a single point of failure controlling security access for over 200 Vault Points of Delivery across four major Amazon regions, meaning when the entire authentication cluster fails, all Vaults become inaccessible. The outages resulted in service interruptions varying from 1-3 hours depending on the Point of Delivery and were caused by software bugs in Veeva’s code that generated excessive calls to the authentication cluster. While Veeva implemented code fixes and hypercare monitoring to address the immediate issues, the incident highlighted the concentration risk inherent in centralized authentication architecture and the potential for similar disruptions to impact thousands of customers simultaneously.

Veeva Systems Inc. confronts intensifying competition from both established enterprise software providers and specialized life sciences vendors targeting its core markets. Salesforce’s launch of Life Sciences Cloud in partnership with IQVIA directly challenges Veeva’s CRM dominance by leveraging Salesforce’s broader platform capabilities and IQVIA’s extensive healthcare data assets. The company has already acknowledged losing two top 20 pharmaceutical customers to Salesforce’s Life Sciences Cloud, demonstrating that competitive pressures present real risks to market share. Market saturation in core pharmaceutical customer segments and pricing pressure from competitors could impact Veeva’s historically strong margins and growth rates, particularly as the company transitions through its platform migration period when customers might be more receptive to competitive alternatives.

Despite diversification efforts, Veeva Systems Inc. maintains significant exposure to customer concentration risk, with its top 10 customers representing approximately 28% of total revenues in fiscal year 2024. The company’s dependence on the life sciences industry creates vulnerability to sector-specific downturns, regulatory changes, or shifts in pharmaceutical R&D spending that could disproportionately impact financial performance. Any material loss of major customers or significant reduction in their technology spending could substantially affect Veeva’s revenue and growth trajectory, particularly given the company’s reliance on large enterprise contracts and multi-year commitments. The company’s concentration within the life sciences sector, while providing deep domain expertise, limits diversification benefits and exposes the business to industry-specific risks including changes in drug development patterns, regulatory environments, or pharmaceutical industry consolidation.

As a cloud-based software provider managing sensitive pharmaceutical and clinical trial data, Veeva Systems Inc. faces substantial cybersecurity and data protection risks that could result in significant customer liability, regulatory penalties, and reputational damage. The company experienced an inadvertent data disclosure in April 2024 where personal information including names and Social Security Numbers was unintentionally sent to a third-party healthcare provider, demonstrating the ongoing risks associated with handling sensitive data. Veeva’s multi-tenant cloud architecture creates concentration risk where a single infrastructure failure or security breach could impact multiple customers simultaneously. The company must continuously adapt to evolving regulatory requirements including data privacy regulations, drug approval processes, and electronic records standards across multiple global jurisdictions, with failure to maintain compliance potentially resulting in customer non-compliance issues or restrictions on market access.

Veeva Systems Inc.’s professional services segment faces structural challenges with declining gross margins and modest growth as customers increasingly adopt self-service models and automation tools. The professional services segment’s gross margin declined to approximately 29.7% in the second quarter of fiscal 2026, reflecting difficulties in maintaining profitability while supporting complex implementations and ongoing customer success initiatives. This margin compression suggests that the traditional high-touch professional services model may not be sustainable as customers become more sophisticated and seek greater autonomy in managing their Veeva implementations. The shift toward automated deployment and customer self-sufficiency may require Veeva to restructure its services organization and pricing models, potentially impacting overall profitability and the company’s ability to provide the level of customer support that has historically driven its high retention rates.

Veeva Systems Inc. faces standard software industry challenges including rapid technological change, evolving customer expectations, and the need for continuous innovation to maintain competitive advantages. The emergence of artificial intelligence and machine learning technologies requires ongoing investment in platform capabilities and may disrupt existing product categories, with the company planning to launch AI agents across its applications starting in December 2025. Economic downturns or reduced pharmaceutical industry spending could impact customer technology budgets and delay implementation projects, affecting the company’s growth trajectory. Additionally, the highly competitive nature of the enterprise software market means Veeva must continuously defend its market position through innovation, customer success, and strategic partnerships while managing cost pressures and investor expectations for sustained double-digit growth rates despite the company’s increasing scale and market maturity.

Save as PDF